SABCS 12014

Genetic analyses identify more mutations and help plan treatment for breast cancer

Genetic analyses identify more mutations and help plan treatment for breast cancer

By

Three studies presented at the 2014 San Antonio Breast Cancer Symposium (SABCS): Cancer risk test detected 105% more mutations in cancer-causing genes than conventional BRCA testing alone; researchers at leading cancer research institutions validate use of companion diagnostic test to detect a DNA scar in tumor that is indicative of a dysfunctional DNA repair pathway; UK researchers evaluated the use of companion diagnostic assays to identify which patients would respond to carboplatin or docetaxel.

Impact of adding bevacizumab to presurgery chemotherapy for triple-negative breast cancer varies

By

The addition of bevacizumab to standard presurgery chemotherapy showed greater benefit in those whose cancers were classified as basal-like by gene expression assay, compared with those whose cancers were nonbasal-like.

Breast cancer has different biological characteristics and outcomes in men and women

By

Results from the largest series of male breast cancer cases ever studied shows improvement in male survival, but not equal to that seen in women with breast cancer.

Adding ultrasound to routine mammography improves cancer detection in dense breasts

By

Among women with denser breasts, an additional ultrasound can detect breast cancers not discovered by mammogram.

Multigene test can predict risk of recurrence for women with ductal carcinoma in situ

By

A multigene test was validated as a predictor of risk of disease recurrence among women treated with breast-conserving surgery alone for ductal carcinoma in situ (DCIS), according to data from a large study.

SABCS: Novel breast cancer drugs show promise in early trials

SABCS: Novel breast cancer drugs show promise in early trials

Pictilisib and pembrolizumab may prolong survival for women with advanced breast cancer, according to data from preliminary studies.

Adding ovarian suppression to tamoxifen reduced recurrence for some premenopausal breast cancer

By

Among premenopausal women with early stage, HR-positive breast cancer, the addition of ovarian suppression to tamoxifen reduced breast cancer recurrence.

Tamoxifen found to lower breast cancer rates among high-risk women in trial

By

The International Breast Cancer Intervention Study-I (IBIS-I) trial found that tamoxifen significantly decreased the incidence of all breast cancers, according to data presented at the 2014 San Antonio Breast Cancer Symposium.

SABCS: Male breast cancer prognosis falls behind that for women

SABCS: Male breast cancer prognosis falls behind that for women

Although survival in male breast cancer has improved, treatment lags behind when compared to the cancer therapy women receive.

Pembrolizumab safe, and even effective in some patients, for triple-negative breast cancer

By

Pembrolizumab was well tolerated and yielded durable responses in patients with metastatic triple-negative breast cancer, according to recent trial data.

Capecitabine does not improve survival in elderly patients with early stage breast cancer

By

In elderly patients with moderate- to high-risk early stage breast cancer for whom standard chemotherapy is too toxic, capecitabine did not improve outcomes when tested as monotherapy, according to recent data.

SABCS: Combined therapy can help younger breast cancer patients

SABCS: Combined therapy can help younger breast cancer patients

Adding tamoxifen to ovarian suppression doesn't provide a significant benefit over tamoxifen alone among premenopausal women with hormone receptor-positive early breast cancer, but the addition of ovarian suppression does benefit some of these women.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs